| Peer-Reviewed

Incidence, Presentation, Characteristics and Short Term Outcomes of Hospitalized Pregnant Women Confirmed SARS-COV-2 Positive

Received: 19 May 2021     Accepted: 19 June 2021     Published: 28 June 2021
Views:       Downloads:
Abstract

To report the incidence, presentation, characteristics and outcomes of a cohort of hospitalized pregnant women who had tested positive for SARS-2, whether or not they had demonstrated signs of Coronavirus Disease-19 (2019-nCov, or Covid-19, ICD-10 U07.1). Material and Methods. The study includes pregnant women, 18 years old and older, who were hospitalized for evaluation or delivery and who had tested positive for SARS-CoV-2 via NP sampling. All were followed by RT PCR and NAA determination between March and December of 2020. Universal testing for SARS-CoV-2 was used throughout the study period. Maternal history and physical screening were conducted upon admission to detect any of the known variables of Covid-19, such as: fatigue, fever (38 C), shortness of breath, and cough. Chest imaging was obtained when indicated. The screening process included domestic or international travel. Additional information collected on 100% of the patients included: maternal ethnicity, body mass index, and 5-digit zip code of maternal residence. Neonates (NN) from SARS-2 positive mothers at delivery admission were tested following the Neonatology service protocol, at age 24 and 48 hours. Additional testing was performed prior to NN discharge when indicated. Results. Of the 3,109 pregnant women who were hospitalized and tested during the study period, 4.3% were reported SARS-2 positive. Of these patients, 13.6% were symptomatic for Covid-19 upon admission; 54% showed a comorbidity; 61% were obese; and one patient needed mechanical ventilation. Table 1 summarizes the cohort characteristics. Table 2 shows the characteristics of the symptomatic women and their clinical course. Conclusion. Our report describes a pregnant patient cohort that had experienced mild to moderate Covid-19 disease. Conflicting studies postulated that pregnant women exposed to SARS-CoV-2 may suffer more serious adverse effects than their non-pregnant counterparts. In view of the wide spectrum of clinical events and the variable severity reported in association with Covid-19 in pregnancy, we believe that quality big data would be beneficial. We therefore recommend strict identification of maternal ethnicity, comorbidities, timing, acuity and severity of the disease. Moreover, health care culture with accurate harmonization of clinical findings and treatments via widespread collaborative efforts, with timely reporting, may assist in understanding the variable pathophysiology of the novel SARS-CoV-2, including its variants, and their conflicting effects on pregnancy.

Published in Journal of Gynecology and Obstetrics (Volume 9, Issue 3)
DOI 10.11648/j.jgo.20210903.16
Page(s) 84-91
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

SARS-CoV-2, Covid 19 Disease, Pregnancy, Vertical Transmission, High Risk Pregnancy, Pandemic

References
[1] Contini C, Di Nuzzo M, Barp N, et al. The novel zoonotic COVID-19 pandemic: An expected global health concern. J Infect Dev Ctries. 2020; 14 (3): 254-264.
[2] Li X, Zai J, Zhao Q, et al. Evolutionary history, potential intermediate anim4al host, and cross-species analyses of SARS-CoV-2. J Med Virol. 2020; 92 (6): 602-611.
[3] Voto C., Berkner, P, Brenner C. (September 10, 2020) Overview of the pathogenesis and treatment of SARS-CoV-2 for clinicians: a comprehesive literature review. Cureus 12 (9) e10357 DOI 10.7759/cureus.10357.
[4] Society for Maternal-Fetal Medicine, Halscott T, Vaught J, Miller E. Management considerations for pregnant patients with COVID-19. Society for Maternal-Fetal Medicine. https://s3.amazonaws.com/cdn.smfm.org/media/2415/SMFM_COVID_Management_of_COVID_pos_preg_patients_7-2-20.PDF_.pdf. Published July 2, 2020. Accessed November 30, 2020.
[5] Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020; 5 (1): 33.
[6] Ng WF, Wong SF, Lam A, et al. The placentas of patients with severe acute respiratory syndrome: a pathophysiological evaluation. Pathology. 2006; 38 (3): 210-2.
[7] Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses. 2020 Feb 10; 12 (2): 194.
[8] Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020; 2 (2): 100118.
[9] Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 in pregnant women: a report based on 116 cases. Am J Obstet Gynecol. 2020; 223 (1): 111.e111-111. e114.
[10] Tekbali A, Grünebaum A, Saraya A, McCullough L, Bornstein E, Chervenak FA. Pregnant vs nonpregnant severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 hospital admissions: the first 4 weeks in New York. Am J Obstet Gynecol. 2020; 223 (1): 126-127.
[11] Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. Coronavirus disease 2019 during pregnancy: a systematic review of reported cases. Am J Obstet Gynecol. 2020; 223 (1): 36-41.
[12] Zahn C. ACOG statement on COVID-19 and pregnancy. American College of Obstetrics and Gynecology. https://www.acog.org/news/news-releases/2020/06/acog-statement-on-covid-19-and-pregnancy. Published June 24, 2020. Accessed August 20, 2020.
[13] U.S. Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of Veklury™ (remdesivir). U.S. Food and Drug Administration. https://www.fda.gov/media/137566/download. Published 2020. Accessed June 20, 2020.
[14] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506.
[15] Schnettler WT, Al Ahwel Y, Suhag A. Severe acute respiratory distress syndrome in coronavirus disease 2019-infected pregnancy: obstetric and intensive care considerations. Am J Obstet Gynecol MFM. 2020; 2 (3): 100120.
[16] Pan D, Sze S, Minhas JS, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine. 2020; 23: 100404.
[17] Scheen AJ. Obesity and risk of severe COVID-19. Rev Med Suisse. 2020; 16 (695): 1115-1119.
[18] Gussow AB, Auslander N, Faure G, Wolf YI, Zhang F, Koonin EV. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. Proc Natl Acad Sci U S A. 2020; 117 (26): 15193-15199.
[19] Personal communication, M Soehnlen, Division of Infectious Diseases MDHHS. June 11. 2020. Breslin N, Baptiste C, Miller R, et al. Coronavirus disease 2019 in pregnancy: early lessons. Am J Obstet Gynecol MFM. 2020; 2 (2): 100111.
[20] Liu D, Li L, Wu X, et al. Pregnancy and Perinatal Outcomes of Women with Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. AJR Am J Roentgenol. 2020; 215 (1): 127-132.
[21] Li N, Han L, Peng M, et al. Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study. Clin Infect Dis. 2020.
[22] Ng WF, Wong SF, Lam A, et al. The placentas of patients with severe acute respiratory syndrome: a pathophysiological evaluation. Pathology. 2006; 38 (3): 210-218.
[23] Pique Regi R, Romero R, Tarca A L, Luca F, Xu Y, Alazizi A et al. Does the human placenta express the canonical cell entry mediators for SARS-CoV-2 ? Elife. 2020 Jul 14, 9: e58716.
[24] Daniels K, Oakeson AM, Hilton G. Steps toward a national disaster plan for obstetrics. Obstet Gynecol. 2014; 124 (1): 154-158.
[25] Committee Opinion No. 726: Hospital Disaster Preparedness for Obstetricians and Facilities Providing Maternity Care. Obstet Gynecol. 2017; 130 (6): e291-e297.
[26] Haeri S, Marcozzi D. Emergency preparedness in obstetrics. Obstet Gynecol. 2015; 125 (4): 959-970.
[27] CDC. Data on COVID-19 during pregnancy: Birth and infant outcomes. https://www.cdc.gov/coronavirus/2019ncov/cases-updates/special-populations/birth-data-on-covid-19.html. Accessed February 10, 2021.
[28] "Lobbying for a 'MENA' category on U.S. Census" Wiltz, Teresea. USA Today. Published 7 October 2014. Accessed 14 February 2021.
[29] Veklury (remdesivir) EUA Letter of Approval, reissued 10/22/2020. Available at https://www.fda.gov/media/137564/download. Accessed February 2, 2021.
[30] Ghi T, di Pasquo E, Mekinian K, Calza L, Frusca T. Sars-CoV-2 in pregnancy. Why is it better than expected? European Journal of Obstetrics & Gynecology and Reproductive biology. 252 (2020): 476-78.
Cite This Article
  • APA Style

    Maheen Irshad, Luna Nasry, Ala Addin Sid Ahmed, Lana Abdole, Federico Mariona. (2021). Incidence, Presentation, Characteristics and Short Term Outcomes of Hospitalized Pregnant Women Confirmed SARS-COV-2 Positive. Journal of Gynecology and Obstetrics, 9(3), 84-91. https://doi.org/10.11648/j.jgo.20210903.16

    Copy | Download

    ACS Style

    Maheen Irshad; Luna Nasry; Ala Addin Sid Ahmed; Lana Abdole; Federico Mariona. Incidence, Presentation, Characteristics and Short Term Outcomes of Hospitalized Pregnant Women Confirmed SARS-COV-2 Positive. J. Gynecol. Obstet. 2021, 9(3), 84-91. doi: 10.11648/j.jgo.20210903.16

    Copy | Download

    AMA Style

    Maheen Irshad, Luna Nasry, Ala Addin Sid Ahmed, Lana Abdole, Federico Mariona. Incidence, Presentation, Characteristics and Short Term Outcomes of Hospitalized Pregnant Women Confirmed SARS-COV-2 Positive. J Gynecol Obstet. 2021;9(3):84-91. doi: 10.11648/j.jgo.20210903.16

    Copy | Download

  • @article{10.11648/j.jgo.20210903.16,
      author = {Maheen Irshad and Luna Nasry and Ala Addin Sid Ahmed and Lana Abdole and Federico Mariona},
      title = {Incidence, Presentation, Characteristics and Short Term Outcomes of Hospitalized Pregnant Women Confirmed SARS-COV-2 Positive},
      journal = {Journal of Gynecology and Obstetrics},
      volume = {9},
      number = {3},
      pages = {84-91},
      doi = {10.11648/j.jgo.20210903.16},
      url = {https://doi.org/10.11648/j.jgo.20210903.16},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20210903.16},
      abstract = {To report the incidence, presentation, characteristics and outcomes of a cohort of hospitalized pregnant women who had tested positive for SARS-2, whether or not they had demonstrated signs of Coronavirus Disease-19 (2019-nCov, or Covid-19, ICD-10 U07.1). Material and Methods. The study includes pregnant women, 18 years old and older, who were hospitalized for evaluation or delivery and who had tested positive for SARS-CoV-2 via NP sampling. All were followed by RT PCR and NAA determination between March and December of 2020. Universal testing for SARS-CoV-2 was used throughout the study period. Maternal history and physical screening were conducted upon admission to detect any of the known variables of Covid-19, such as: fatigue, fever (38 C), shortness of breath, and cough. Chest imaging was obtained when indicated. The screening process included domestic or international travel. Additional information collected on 100% of the patients included: maternal ethnicity, body mass index, and 5-digit zip code of maternal residence. Neonates (NN) from SARS-2 positive mothers at delivery admission were tested following the Neonatology service protocol, at age 24 and 48 hours. Additional testing was performed prior to NN discharge when indicated. Results. Of the 3,109 pregnant women who were hospitalized and tested during the study period, 4.3% were reported SARS-2 positive. Of these patients, 13.6% were symptomatic for Covid-19 upon admission; 54% showed a comorbidity; 61% were obese; and one patient needed mechanical ventilation. Table 1 summarizes the cohort characteristics. Table 2 shows the characteristics of the symptomatic women and their clinical course. Conclusion. Our report describes a pregnant patient cohort that had experienced mild to moderate Covid-19 disease. Conflicting studies postulated that pregnant women exposed to SARS-CoV-2 may suffer more serious adverse effects than their non-pregnant counterparts. In view of the wide spectrum of clinical events and the variable severity reported in association with Covid-19 in pregnancy, we believe that quality big data would be beneficial. We therefore recommend strict identification of maternal ethnicity, comorbidities, timing, acuity and severity of the disease. Moreover, health care culture with accurate harmonization of clinical findings and treatments via widespread collaborative efforts, with timely reporting, may assist in understanding the variable pathophysiology of the novel SARS-CoV-2, including its variants, and their conflicting effects on pregnancy.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Incidence, Presentation, Characteristics and Short Term Outcomes of Hospitalized Pregnant Women Confirmed SARS-COV-2 Positive
    AU  - Maheen Irshad
    AU  - Luna Nasry
    AU  - Ala Addin Sid Ahmed
    AU  - Lana Abdole
    AU  - Federico Mariona
    Y1  - 2021/06/28
    PY  - 2021
    N1  - https://doi.org/10.11648/j.jgo.20210903.16
    DO  - 10.11648/j.jgo.20210903.16
    T2  - Journal of Gynecology and Obstetrics
    JF  - Journal of Gynecology and Obstetrics
    JO  - Journal of Gynecology and Obstetrics
    SP  - 84
    EP  - 91
    PB  - Science Publishing Group
    SN  - 2376-7820
    UR  - https://doi.org/10.11648/j.jgo.20210903.16
    AB  - To report the incidence, presentation, characteristics and outcomes of a cohort of hospitalized pregnant women who had tested positive for SARS-2, whether or not they had demonstrated signs of Coronavirus Disease-19 (2019-nCov, or Covid-19, ICD-10 U07.1). Material and Methods. The study includes pregnant women, 18 years old and older, who were hospitalized for evaluation or delivery and who had tested positive for SARS-CoV-2 via NP sampling. All were followed by RT PCR and NAA determination between March and December of 2020. Universal testing for SARS-CoV-2 was used throughout the study period. Maternal history and physical screening were conducted upon admission to detect any of the known variables of Covid-19, such as: fatigue, fever (38 C), shortness of breath, and cough. Chest imaging was obtained when indicated. The screening process included domestic or international travel. Additional information collected on 100% of the patients included: maternal ethnicity, body mass index, and 5-digit zip code of maternal residence. Neonates (NN) from SARS-2 positive mothers at delivery admission were tested following the Neonatology service protocol, at age 24 and 48 hours. Additional testing was performed prior to NN discharge when indicated. Results. Of the 3,109 pregnant women who were hospitalized and tested during the study period, 4.3% were reported SARS-2 positive. Of these patients, 13.6% were symptomatic for Covid-19 upon admission; 54% showed a comorbidity; 61% were obese; and one patient needed mechanical ventilation. Table 1 summarizes the cohort characteristics. Table 2 shows the characteristics of the symptomatic women and their clinical course. Conclusion. Our report describes a pregnant patient cohort that had experienced mild to moderate Covid-19 disease. Conflicting studies postulated that pregnant women exposed to SARS-CoV-2 may suffer more serious adverse effects than their non-pregnant counterparts. In view of the wide spectrum of clinical events and the variable severity reported in association with Covid-19 in pregnancy, we believe that quality big data would be beneficial. We therefore recommend strict identification of maternal ethnicity, comorbidities, timing, acuity and severity of the disease. Moreover, health care culture with accurate harmonization of clinical findings and treatments via widespread collaborative efforts, with timely reporting, may assist in understanding the variable pathophysiology of the novel SARS-CoV-2, including its variants, and their conflicting effects on pregnancy.
    VL  - 9
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Wayne State University School of Medicine, Detroit, Michigan USA

  • Wayne State University School of Medicine, Detroit, Michigan USA

  • Wayne State University School of Medicine, Detroit, Michigan USA

  • Wayne State University School of Medicine, Detroit, Michigan USA

  • Michigan Perinatal Associates, Beaumont Health Dearborn, Michigan USA

  • Sections